Press Releases Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
17.04 ^USD	-1.33%		-13.41%	-2.57%

01-13	AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says	MT
01-12	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI

Press Releases

01-12	Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)	BU
01-12	Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	BU
01-10	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
01-06	Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	BU
12-05	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
11-07	Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China	BU
11-04	Summit Therapeutics to Present at Upcoming Investor Conferences	BU
11-03	Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025	AQ
31/10/25	Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025	BU
22/10/25	Summit Therapeutics Raises $500 Million in Private Placement	BU
20/10/25	Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025	BU
19/10/25	Summit Therapeutics : Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China	PU
19/10/25	Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China	BU
18/10/25	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT	PR
17/10/25	Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer	BU
16/10/25	Summit Therapeutics to Host ESMO Data Update Third Quarter Earnings Call on October 20 2025	AQ
15/10/25	Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025	BU
13/10/25	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT	PR
08/10/25	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT	PR
03/10/25	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT	PR
28/09/25	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT	PR
24/09/25	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
24/09/25	HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025	BU
23/09/25	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT	PR
18/09/25	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Press Releases

Filters